FDA reports double-digit rise in antibiotics use on farms; Zoetis adds Actavis exec to board; Canadian researchers develop rapid avian flu test;

> The FDA released its 2013 report on antibiotics use, which showed a 17% increase in the use of the drugs for food animals between 2009 and 2013. Release

> Zoetis ($ZTS), which has been under pressure from activist investor Bill Ackman, announced that it has expanded its board of directors and appointed Paul Bisaro, executive chairman of Actavis ($ACT), to it. Release

> Researchers at the University of Guelph have developed an instant test for avian flu. Release

> Putney won FDA approval for Tiletamine-Zolazepam (tiletamine HCl and zolazepam HCl) injectable, the generic of Telazol, an anesthetic made by Zoetis. Release

> The FDA said it has withdrawn the antifreeze antidote Antizol-Vet from the market at the request of its maker, Paladin Labs. Release

> Boehringer Ingelheim's Vetmedica announced that its product Vetmedin Chewable has been approved to treat pre-clinical dilated cardiomyopathy in doberman pinschers. Article (reg. req.)

> Kansas State University's veterinary school has established the Center of Excellence for Vector-Borne Diseases, which will focus on controlling infectious diseases in both people and animals. Release

> Colorado State University spinoff VetDC has raised $2.1 million to develop a drug for canine lymphoma. Article

> The Roslin Institute in the U.K. has received £2.7 ($3.9 million) in funding to study viruses in poultry and pigs, as well as gut diseases in farmed cattle. Article

> Epica Medical Innovations has partnered with Henry Schein ($HSIC), which will distribute its CT scanners and X-ray technologies to veterinary clinics. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…